164 related articles for article (PubMed ID: 38163276)
1. Rational prediction of immunogenicity clustering through cross-reactivity analysis of thirteen SARS-CoV-2 variants.
Liang Z; Tong J; Sun Z; Liu S; Wu J; Wu X; Li T; Yu Y; Zhang L; Zhao C; Lu Q; Nie J; Huang W; Wang Y
J Med Virol; 2024 Jan; 96(1):e29314. PubMed ID: 38163276
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
J Virol; 2024 Jul; ():e0067824. PubMed ID: 38953380
[TBL] [Abstract][Full Text] [Related]
3. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibody response to SARS-CoV-2 bivalent mRNA vaccine in SIV-infected rhesus macaques: Enhanced immunity to XBB subvariants by two-dose vaccination.
Faraone JN; Wang X; Qu P; Zheng YM; Vincent E; Xu H; Liu SL
J Med Virol; 2024 Mar; 96(3):e29520. PubMed ID: 38528837
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J
Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825
[TBL] [Abstract][Full Text] [Related]
6. Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines.
Chalkias S; McGhee N; Whatley JL; Essink B; Brosz A; Tomassini JE; Girard B; Edwards DK; Wu K; Nasir A; Lee D; Avena LE; Feng J; Deng W; Montefiori DC; Baden LR; Miller JM; Das R
J Infect Dis; 2024 Feb; ():. PubMed ID: 38349280
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV.
Vergori A; Matusali G; Lepri AC; Cimini E; Fusto M; Colavita F; Gagliardini R; Notari S; Mazzotta V; Mariotti D; Cicalini S; Girardi E; Vaia F; Maggi F; Antinori A;
Int J Infect Dis; 2023 Sep; 134():195-199. PubMed ID: 37343783
[TBL] [Abstract][Full Text] [Related]
8. Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1.
Liu S; Liang Z; Nie J; Gao WB; Li X; Zhang L; Yu Y; Wang Y; Huang W
Emerg Microbes Infect; 2023 Dec; 12(2):2225638. PubMed ID: 37313604
[TBL] [Abstract][Full Text] [Related]
9. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
[TBL] [Abstract][Full Text] [Related]
10. Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography.
Rössler A; Netzl A; Knabl L; Bante D; Wilks SH; Borena W; von Laer D; Smith DJ; Kimpel J
Nat Commun; 2023 Aug; 14(1):5224. PubMed ID: 37633965
[TBL] [Abstract][Full Text] [Related]
11. Low neutralization of SARS-CoV-2 Omicron BA.5.2.48, BF.7.14, XBB.1 subvariants by homologous or heterologous booster.
Li J; Mao H; Song W; Chen Y; Feng Y; Li J; Su L; Li X; Shi W; Wu Y; Huang C; Zhang Y; Chen K
J Med Virol; 2023 Dec; 95(12):e29306. PubMed ID: 38084772
[TBL] [Abstract][Full Text] [Related]
12. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.
Kurhade C; Zou J; Xia H; Liu M; Chang HC; Ren P; Xie X; Shi PY
Nat Med; 2023 Feb; 29(2):344-347. PubMed ID: 36473500
[TBL] [Abstract][Full Text] [Related]
13. Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents.
Abul Y; Nugent C; Vishnepolskiy I; Wallace T; Dickerson E; Holland L; Esparza I; Winkis M; Wali KT; Chan PA; Baier RR; Recker A; Kaczynski M; Kamojjala S; Pralea A; Rice H; Osias O; Oyebanji OA; Olagunju O; Cao Y; Li CJ; Roederer A; Pfeifer WM; King CL; Bosch J; Nanda A; McNicoll L; Mujahid N; Raza S; Tyagi R; Wilson BM; White EM; Canaday DH; Gravenstein S; Balazs AB
medRxiv; 2024 Mar; ():. PubMed ID: 38585784
[TBL] [Abstract][Full Text] [Related]
14. Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.
Bellusci L; Grubbs G; Sait S; Yonker LM; Randolph AG; Novak T; Kobayashi T; ; Khurana S
Nat Commun; 2023 Dec; 14(1):7952. PubMed ID: 38040697
[TBL] [Abstract][Full Text] [Related]
15. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
Du P; Li N; Xiong X; Tang S; Dai Q; Liu Z; Wang T; Gu X; Zhou Z
J Med Virol; 2022 Sep; 94(9):4287-4293. PubMed ID: 35614524
[TBL] [Abstract][Full Text] [Related]
16. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
[TBL] [Abstract][Full Text] [Related]
17. Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster.
Wang X; Jiang S; Ma W; Li X; Wei K; Xie F; Zhao C; Zhao X; Wang S; Li C; Qiao R; Cui Y; Chen Y; Li J; Cai G; Liu C; Yu J; Li J; Hu Z; Zhang W; Jiang S; Li M; Zhang Y; Wang P
Cell Host Microbe; 2024 Jan; 32(1):25-34.e5. PubMed ID: 38029742
[TBL] [Abstract][Full Text] [Related]
18. Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3.
Faraone JN; Qu P; Goodarzi N; Zheng YM; Carlin C; Saif LJ; Oltz EM; Xu K; Jones D; Gumina RJ; Liu SL
Emerg Microbes Infect; 2023 Dec; 12(2):2270069. PubMed ID: 37819267
[TBL] [Abstract][Full Text] [Related]
19. Omicron Variant-Specific Serological Imprinting Following BA.1 or BA.4/5 Bivalent Vaccination and Previous SARS-CoV-2 Infection: A Cohort Study.
Baerends EAM; Reekie J; Andreasen SR; Stærke NB; Raben D; Nielsen H; Petersen KT; Johansen IS; Lindvig SO; Madsen LW; Wiese L; Iversen MB; Benfield T; Iversen KK; Larsen FD; Andersen SD; Juhl AK; Dietz LL; Hvidt AK; Ostrowski SR; Krause TG; Østergaard L; Søgaard OS; Lundgren J; Tolstrup M
Clin Infect Dis; 2023 Nov; 77(11):1511-1520. PubMed ID: 37392436
[TBL] [Abstract][Full Text] [Related]
20. A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants.
Wang R; Huang H; Yu C; Sun C; Ma J; Kong D; Lin Y; Zhao D; Zhou S; Lu J; Cao S; Zhang Y; Luo C; Li X; Wang Y; Xie L
Sci China Life Sci; 2023 Aug; 66(8):1818-1830. PubMed ID: 36598621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
